Navigation Links
Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
Date:9/17/2008

n, Quark has a broad pipeline of siRNA drug candidates based a novel structure developed internally. The Company expects to utilize the structure to develop additional RNAi drug candidates

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at http://www.quarkpharma.com

Quark Pharmaceuticals, Inc.

Juliana Friedmann

+972 89 30 5111 /

jfriedman@quarkpharma.com

The Ruth Group (investors / media)

Sara Ephraim / Janine McCargo

(646) 536-7004 / 7033

sephraim@theruthgroup.com

jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
2. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
5. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
6. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
7. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
8. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
9. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
10. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
11. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... STONY BROOK, NY (PRWEB) July 30, 2014 ... (OTCQB: APDN), (Twitter: @APDN), a biotechnology firm that provides ... Dr. Michael E. Hogan, Ph.D. Vice President of Life ... in mid-September. , Dr. Hogan will lead ... to form business relationships with biotech and healthcare customers, ...
(Date:7/30/2014)... Scranton, PA (PRWEB) July 30, 2014 ... Flametec® family of products, designed to meet Factory Mutual ... cleanroom equipment materials such as wet benches, process tools, ... to worker safety and damage to semiconductor wafers used ... provides a flame-retardant PVC solution with excellent workability ...
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. ... received the Day 180 List of Outstanding Issues (LOI) ... for Human Use (CHMP) for the NB32 Marketing Authorization ... SR) is an investigational drug candidate being evaluated for ... earlier Day 120 time point were adequately addressed by ...
(Date:7/30/2014)... , July 30, 2014 Researchers often ... interrogate biology, but such devices can do much ... As such, researchers have looked to patterned ... vitro metabolic engineering to characterize – and ... New devices are envisioned to recreate animal and ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4
... Foundation for Angelman Syndrome Therapeutics (FAST) announces it will ... treatment for the rare genetic disorder, Angelman Syndrome (AS).  ... study will examine if the off label administration ... with Angelman Syndrome. Minocycline, an FDA approved antibiotic, is ...
... Feb. 14, 2012  Milo Biotechnology will receive $250,000 ... assistance and some capital into early stage Northeast ... a therapy to increase muscle strength and improve ... Milo is the 61st company in JumpStart,s portfolio. ...
... Gen-Probe Incorporated (NASDAQ: GPRO ) today reported ... in the quarter grew 16%, to a new record of ... to a new high of $0.72. "Gen-Probe finished ... quarter while clinical diagnostics revenues continued their solid growth," said ...
Cached Biology Technology:Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial 2Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial 3JumpStart Invests $250,000 in Milo Biotechnology 2Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 2Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 3Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 4Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 5Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 6Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 7Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 8Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 9Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 10Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 11Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 12Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 13Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 14Gen-Probe Reports Financial Results for the Fourth Quarter of 2011 15
(Date:7/30/2014)... of cells types. Researchers would like to understand how to ... that make up the organs and other structures of living ... of sugars that dangle from proteins on surfaces of cells. ... Diego, has created synthetic molecules that can stand in for ... direct the process, they report in the Journal of ...
(Date:7/29/2014)... New research by academics in the University of Bristol,s ... we take liquid calories into account when planning meals. ... for the Study of Ingestive Behavior Conference (SSIB 2014) ... August], argues that we do. , The team was ... the School of Experimental Psychology. , As part of ...
(Date:7/29/2014)... Research and Markets  has announced the addition of ... report to their offering. ... refers to applications and technologies that are used for ... company,s operations. BI help organizations to acquire comprehensive knowledge ... on sales, production, and internal operations. ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2
... membranes could help phytoplankton cope with nutrient scarcity in the ... of the National Oceanography Centre has shown that a species ... of its cell membranes in response to changes in nutrient ... for nutrient cycling and the population dynamics of phytoplankton in ...
... JUPITER, FL, December 16, 2010 Scientists from ... shown that prions, bits of infectious protein that can ... (BSE) or "mad cow disease," have the ability to ... In this regard, although they lack DNA and RNA, ...
... Researchers funded by the Biotechnology and Biological Sciences Research ... clue that may help to explain why the earliest evidence ... ago, when atmospheric oxygen levels on the planet rose sharply ... The team, led by Professor Chris Schofield, has found that ...
Cached Biology News:Efficient phosphorus use by phytoplankton 2Scripps Research scientists show prions mutate and adapt to host environment 2Scripps Research scientists show prions mutate and adapt to host environment 3550 million years ago rise in oxygen drove evolution of animal life 2
Human Serpin B5/Maspin Affinity Purified Polyclonal Ab...
... S.J. Allen (1995) This book ... authorities on current issues relating to the ... major advances have been made recently which ... Topics include molecular neuropathology through clinical and ...
Normal human serum, single donor...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
Biology Products: